Then in 2002, a study called the Women's Health Initiative found that women taking hormone replacement therapy may have an increased risk of of breast cancer diagnoses, not mortality, but diagnoses. The study was not statistically significant, but it triggered a media frenzy and led to the FDA applying unscientific black box warnings to all hormone replacement therapy products in 2003. The label was designed to frighten women and to silence doctors. It warned of diseases and dangers that the data simply did not support. (08:27–08:42)
CLAIM
Asserts that the FDA applied black box warnings to hormone replacement therapy products based on a non-statistically significant study.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
